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Pex5p, a receptor for peroxisomal matrix proteins
with a type 1 peroxisome targeting signal (PTS1), has
been proposed to cycle from the cytoplasm to the perox-
isomal membrane where it docks with Pex14p and
Pex13p, the latter an SH3 domain-containing protein.
Using in vitro binding assays we have demonstrated
that binding of Pex5p to Pex14p is enhanced when
Pex5p is loaded with a PTS1-containing peptide. In con-
trast, Pex5p binding to Pex13p, which involves only the
SH3 domain, occurs at 20–40-fold lower levels and is
reduced when Pex5p is preloaded with a PTS1 peptide.
Pex14p was also shown to bind weakly to the Pex13p
SH3 domain. Site-directed mutagenesis of the Pex13p
SH3 domain attenuated binding to Pex5p and Pex14p,
consistent with both of these proteins being binding
partners for this domain. The SH3 binding site in Pex5p
was determined to lie within a 114-residue peptide
(Trp100-Glu213) in the amino-terminal region of the pro-
tein. The interaction between this peptide and the SH3
domain was competitively inhibited by Pex14p. We in-
terpret these data as suggesting that docking of the
Pex5p-PTS1 protein complex at the peroxisome mem-
brane occurs at Pex14p and that the Pex13p SH3 domain
functions as an associated component possibly involved
in sequestering Pex5p after relinquishment of the PTS1
protein cargo to components of the translocation
machinery.
The import of proteins into the peroxisomal matrix from
their site of synthesis on cytosolic ribosomes requires at least
two targeting signals. Peroxisomal targeting signal (PTS)1 type
1 consists of a tripeptide sequence (Ser-Lys-Leu, or conserved
variant) at the extreme carboxyl terminus and is utilized by the
majority of matrix proteins (1). PTS2 is an amino-terminal
signal that is used by a small number of proteins (2, 3). The
PTS1 receptor has been identified as Pex5p, a protein with TPR
domains that bind the PTS1 signal (4, 5) and the PTS2 receptor
as Pex7p, a member of the WD-40 protein family (6–9). The
intracellular location of these receptors remains controversial.
The Pichia pastoris Pex5 protein (formerly called Pas8p), was
initially reported as a peroxisomal integral membrane protein
(4). More recently, another peroxisomal integral membrane
protein, Pex13p, has been demonstrated to bind Pex5p via a
cytoplasmically oriented SH3 domain (10–12), and a reinves-
tigation of the subcellular localization of Pex5p in these studies
concluded that Pex5p was predominantly cytoplasmic, with a
small proportion associated with the peroxisomal membrane.
Yeast pex13 mutant strains exhibit defective PTS1 protein
import (10–12) and also a marked reduction in the level of
membrane-associated Pex5p (10). These findings have been
taken to suggest that Pex5p acts as a cycling PTS1 receptor
that is docked at the peroxisomal membrane by Pex13p.
Interestingly, pex13 mutants also display defective PTS2
protein import (10–12). The recent finding that the amino-
terminal region of Pex13p binds Pex7p (13) is one possible
explanation for this effect. Pex14p, a peripheral membrane
protein on the cytoplasmic surface of the peroxisome, has also
been shown to bind Pex7p, a finding implicating it as a docking
protein for this receptor (14). Interestingly, Pex14p has also
been shown to bind Pex5p and also weakly to the Pex13p SH3
domain. Another peroxisomal peripheral membrane protein,
Pex17p, is also involved in these import pathways and has been
shown to associate with Pex14p (15). Thus, Pex13p and Pex14p
represent putative convergence points for the two import path-
ways and provide initial direct evidence of a common translo-
cation machinery for PTS1 and PTS2 proteins.
Despite these important findings, many elements of the im-
port mechanisms remain unknown. In particular, the different
roles of the proteins implicated in docking Pex5p at the perox-
isome membrane have not been resolved. Thus, Pex13p and
Pex14p may compete for binding of Pex5p or form part of a
protein import cascade in which a receptor-cargo protein com-
plex moves from one component to another (14). A clarification
of the interactions among Pex5p, Pex13p, and Pex14p is there-
fore warranted, and in this paper we report on molecular anal-
yses that address these questions. On the basis of the findings
presented, we propose a revised model for the interactions of
Pex5p, Pex13p, and Pex14p in the PTS1 import pathway.
EXPERIMENTAL PROCEDURES
Materials—Restriction enzymes were purchased from Roche Molec-
ular Biochemicals (Germany). Polymerase chain reaction (PCR) was
performed using EXPAND DNA polymerase (Roche Molecular Bio-
chemicals). Oligonucleotide primers were synthesized by Pacific Oligos
(Australia) or Bresatec (Adelaide, Australia). [35S]Methionine was pur-
chased from Amersham Pharmacia Biotech (Buckingham Shire, U. K.)
or Bresatec. Peptides were synthesized by Chiron Technologies (Mel-
bourne, Australia).
Construction, Expression, and Purification of GST Fusion Proteins—
DNA fragments corresponding to Pex13p amino acids Pro276-Pro348,
Pro276-Thr380, and His252-Thr380 were generated via PCR using the
following primer pairs
A: 59-GGGGATCCCACGAAGTTGGAGTT-39 and 59-GCGAATATGC-
GGCCGCGGGTCGTTGATGTCGTTCAATG-39,
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B: 59-GGGGATCCCACGAAGTTGGAGTT-39 and 59-GGGCTCGAG-
TAGTTAGCTATTTAGCTATTATG-39,
C: 59-GGGGATCCTTCATCTTGCTGACACCAGTCAAAATGAATG-
G-39 and 59-GGGCTCGAGTAGTTAGCTATTTAGCTATTATG-39, re-
spectively, with the vector template pDC120. pDC120 contains the
entire PEX13 open reading frame as a PvuII-HindIII fragment cloned
between the EcoRV-HindIII sites of the HIS41-Escherichia coli-P. pas-
toris shuttle vector pSG934 (10, 16). The DNA fragments, which were
constructed to include a terminal 59-BamHI site and 39-NotI site (A) or
a 59-BamHI site and a 39-XhoI site (B and C), were then cloned into the
corresponding restriction enzyme sites of the bacterial expression vec-
tor pGEX-5x-3 (Amersham Pharmacia Biotech). The resulting GST
fusion constructs were designated GST-SH3, GST-SH3-COOH, and
GST-MSH3-COOH, respectively. The construction of the fusion protein
between GST and the human Pex13p SH3 domain has been described
previously (10). A DNA fragment, incorporating the entire P. pastoris
PEX14 open reading frame, was generated by a SalI-NotI restriction
digest of the plasmid pJL59/pp14F1.2 This fragment was then cloned
between the XhoI and NotI sites of pGEX-5x-3, creating pGST-PEX14.
The GST fusion plasmids were electroporated into electrocompetent
DH10B E. coli cells (Life Technologies, Inc.) using a GenePulser (Bio-
Rad) according to the manufacturer’s protocol and then plated onto LB
agar (Life Technologies, Inc.) containing 100 mg/ml ampicillin in order
to select for successful transformants. Positive constructs were identi-
fied via restriction enzyme digest and confirmed by direct sequencing
using dideoxy terminator cycle sequencing on an Applied Biosystems
373 DNA sequencer.
GST fusion proteins were expressed by seeding 1-liter overnight
cultures of LB containing 100 mg/ml ampicillin with DH10B cells har-
boring the relevant plasmid, to an absorbance at 600 nm (A600) of 0.05.
Cells were grown to an A600 of 0.5, at which point expression of the GST
fusion protein was induced by the addition of 0.5 mM isopropyl-b-D-
thiogalctopyranoside (Progen Industries, Brisbane, Australia). Cells
were grown for a further 3 h, pelleted by centrifugation, resuspended in
GST lysis buffer (50 mM Hepes, pH 8.0, 10% ethylene glycol, 1% Triton
X-100, 5 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride), and
frozen at 220 °C. The suspensions were thawed and sonicated, and the
lysate was cleared by centrifugation (30 min at 12,000 3 g) and mixed
gently for 1 h at room temperature with 1 ml of GSH resin (Amersham
Pharmacia Biotech). The lysate/resin mixes were loaded into a column
and washed with approximately 40 ml of lysis buffer. The GST fusion
proteins were eluted from the resin with 50 mM Tris-HCl and 10 mM
glutathione and stored at 280 °C until required. The purity of fusion
proteins was confirmed by SDS-polyacrylamide gel electrophoresis.
Site-directed Mutagenesis—The point mutations E291K, E291Q,
E296K, and E296Q were generated by degenerate oligonucleotide mu-
tagenesis of the Pex13p-encoding plasmid pDC120. The following oli-
gonucleotides were used to generate PCR products, incorporating the
point mutations, from the template pDC120: 59-GACGGGCCCTTTAC-
GATTTCAATCCTAAGAATGAAG-39 and 59-GACGGGCCCTTTACGA-
TTTCAATCCTCAGAATGAAG-39, which incorporate a 59-ApaI site and
the point mutations E291K and E291Q, respectively; 59-GCGGAGCT-
CACCTCTAGCAAGTTTAAGCTTCATTTCTTC-39 and 59-GCGGAGCT-
CACCTCTAGCAAGTTTCAGCTGCATTTCTTC-39, which incorporate a
59-SacI site and the point mutations E296K and E296Q, respectively;
59-GAGAAGAAGTCGAAAGGACACAGTATTTTCGAAGGG-39 (for
E291K/Q) and 59-GAAACGAATCATGGGCAAGTTGATGGG-39 (for
E296K/E296Q). The fragments were digested with ApaI and HindIII
(for E291K/E291Q) or SacI and EcoRI (for E296K/E296Q) and cloned
into the corresponding sites of pDC120. The mutations E318K and
W321LW322L were introduced into pDC120 with the Gene Editor sit-
e-directed mutagenesis system (Promega, Madison, WI) using the olig-
onucleotides 59-CCAACCAGAAGTCTACTTGG-39 and 59-CCAGGAGT-
CTACTTTGTTGAAATGCAGAACTCGGG-39, respectively, according to
the manufacturer’s protocol. All plasmid constructs were confirmed by
sequencing. GST fusion constructs incorporating these mutations were
prepared by the procedure used for the generation of GST-SH3, as
described above.
In Vivo Growth Assays of Pex13p SH3 Domain Mutants—Electro-
competent P. pastoris pex13D, his4D yeast (10) was electroporated with
site-directed mutants of PEX13 in the plasmid pDC120, using a Gene
Pulser Electroporater (Bio-Rad), according to the manufacturer’s rec-
ommendations. Transformed yeast was plated onto SSD agar plates (1
M sorbitol, 1.7 g/liter yeast nitrogen base without amino acids and
ammonium sulfate (Difco Laboratories, Detroit, MI), 5 g/liter ammo-
nium sulfate, 2% dextrose, 20 g/liter bacteriological agar) to select for
HIS1 transformants, which were subsequently tested for their ability
to grow in minimal media containing methanol, SM (1.7 g/liter yeast
nitrogen base without amino acids and ammonium sulfate (Difco Lab-
oratories), 5 g/liter ammonium sulfate, 0.5% methanol) (17).
Construction of Expression Plasmids for Coupled in Vitro Transcrip-
tion/Translation—The plasmid pJEK4-3, encoding the entire PEX5
open reading frame, has been described previously (18). pJEK5–
4DNP8, encoding amino acids 206–576 (STOP) of Pex5p was created by
deletion mutagenesis of pJEK4-3. pAU203 (encoding amino acids
1–108) was created by digesting pJEK4-3 with NcoI and EcoRI and then
ligating the vector remnant, creating a STOP codon directly after the
NcoI-EcoRI ligation site. pAU206(56–576) was created by PCR using
the 59-oligonucleotide (59-CCCCGCGGGAATGGAAAGGCAGCAAATG-
39), with a 59-KspI site, and a 39-oligonucleotide (59-GCAACCATGGG-
ATCCTTCAT-39), with a 59-NcoI site. The PCR product was then cloned
into pJEK4-3 between the KspI and NcoI sites. The primers used to
generate DNA fragments for the following constructs were: pAU-
201(1–266), 59-GTGCCGCGGGAAGTAATCC-39 and 59-GGAATTCTC-
AGTATTCTCCGTAATTGAGCC-39; pAU202(110–266), 59-TCCCCGC-
GGCCCATGGTTGCAAACGCTCCATCTGCC-39 and 59-GGAATTCTC-
AGTATTCTCCGTAATTGAGCC-39; pAU205(1–55), 59-GTGCCGCGG-
GAAGTAATCC-39 and 59-GGAATTCTCATGGGGACATGGTACTTTC-
ATTTC-39; pAU207(56–266), 59-CCCCGCGGGAATGGAAAGGCAGC-
AAATG-39 and 59-GGAATTCTCAGTATTCTCCGTAATTGAGCC-39;
pAU208(1–99), 59-GTGCCGCGGGAAGTAATCC-39 and 59-GGAATTC-
TCAGCTATTGTTTGCTACTTGCTG-39; pAU210(56–127), 59-CCCCG-
CGGGAATGGAAAGGCAGCAAATG-39 and 59-GGAATTCTCAGTTAG-
TTGATTGAACAGGTG-39; pAU211(100–213), 59-CCCCGCGGGATGG-
AACCAAGAGTTTCGAATG-39 and 59-GGAATTCTCATTCTTGGGTT-
TTACTGTTCAAC-39; pAU212(100–195), 59-CCCCGCGGGATGGAAC-
CAAGAGTTTCGAATG-39 and 59-GGAATTCTCATTGTGTCTGTGAT-
TGTTCTG-39; and pAU213(100–174), 59-CCCCGCGGGATGGAACCA-
AGAGTTTCGAATG-39 and 59-GGAATTCTCAACGGTTCATGCTCCC-
GC-39. In each case, the plasmid pJEK4-3 was used as a template for
PCR, the 59-oligonucleotide contained a 59-KspI site and the 39-oligonu-
cleotide a 59-STOP codon followed by an EcoRI site. The PCR fragments
were cloned between the KspI and EcoRI sites of pJEK4-3. pAU401 was
created by PCR amplification of the entire PEX14 open reading frame
from the plasmid pJL59/pp14F1 using the 59-oligonucleotide 59-CAAC-
TGCAGATGATATTCTGGATTCTTAGGCTATC-39, with a 59-PstI site,
and the 39-oligonucleotide 59-CGCGGATCCATGACAACTCAGCTTTG-
AGCTGCC-39, with a 59-BamHI site. The DNA fragment was then
cloned between the PstI and sites of the mammalian expression vector
pSP64 poly(A) (Promega). All constructs were confirmed by direct se-
quencing as described above.
In Vitro Overlay Binding Assay—[35S]Methionine-labeled proteins
were created by coupled in vitro transcription and translation using the
rabbit reticulocyte lysate TNTt SP6 expression system (Promega) as
described by the manufacturer. Dot blots were performed using a vac-
uum manifold to immobilize 0.2 nmol of GST fusion protein to nitrocell-
ulose membrane (Bio-Rad). A negative control of no protein was used to
monitor background binding. The nitrocellulose was then blocked for
2 h at room temperature using TBST (137 mM NaCl, 3 mM KCl, 25 mM
Tris-HCl, pH 7.4, 0.1% Tween 20) or TBS (137 mM NaCl, 3 mM KCl, 25
mM Tris-HCl, pH 7.4) containing 10% w/v skimmed milk powder
(BLOTTO). After blocking, immobilized proteins were probed (over-
night at 4 °C) with 35S-labeled protein in 1 ml of 10% BLOTTO. The
blots were then washed in TBST or TBS (4 3 5 min) and dried at room
temperature. At this stage, some of the dried membranes were exposed
overnight to x-ray film (Eastman Kodak, Rochester, NY) and bound
radioactivity determined using densitometry and the analysis software
NIH Image, version 1.61.
To quantify the level of binding between the various GST fusions and
35S-labeled protein, individual dots were cut from the dried nitrocellu-
lose and placed in 10 ml of ACS or BCS scintillation fluid (Amersham
Pharmacia Biotech). Radioactivity was determined using a 2000CA
Tri-Carb liquid scintillation analyzer (United Technologies Packard).
When comparing the degree of binding of different 35S-labeled pro-
teins, equivalent mol of protein were used as determined by methionine
labeling using the TNTt SP6 expression system (Promega). Briefly, in
triplicate measurements, 2 ml of coupled transcription/translation re-
action product was added to 98 ml of 1 M NaOH and 2% H202, vortexed
and incubated at 37 °C for 10 min. 900 ml of ice-cold 25% trichloroacetic
acid and 2% amino acid mixture was added and the mix incubated on ice
for 30 min to precipitate the translation product. 250 ml of the trichlor-
oacetic acid/protein mix was then vacuum filtered onto GF/C filter
paper (Whatman, Maidstone, U. K.) pre-wet with 5% trichloroacetic2 S. J. Gould, manuscript in preparation.
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acid; the filter was rinsed three times with 1 ml of ice-cold 5% trichlor-
oacetic acid and once with 1 ml of acetone and then dried at room
temperature. Dry filter paper was then placed in 10 ml of scintillation
fluid and counted, as above, and the results used to determine mol of
protein (based on methionine content) for use in dot blot assays as well
as the relative molar binding levels.
Competitive binding between radiolabeled Pex5p and unlabeled
Pex5p for membrane-immobilized GST-SH3 was tested by adding a
constant volume (30 ml) of 35S-labeled Pex5p with various molar ratios
(up to 90 ml) of unlabeled Pex5p, both created by in vitro transcription/
translation, in 1 ml of TBST BLOTTO. Competitive binding between
Pex5p and the Trp100-Glu213 peptide for membrane-immobilized GST-
SH3 was tested by adding a constant volume (15 ml) of 35S-labeled
Pex5p with various molar ratios (up to 50 ml) of unlabeled Trp100-Glu213
peptide, both created by in vitro transcription/translation, in 1 ml of
TBST BLOTTO. Competitive binding between the Trp100-Glu213 pep-
tide and Pex14p for membrane-immobilized GST-SH3 was tested by
adding a constant volume (10 ml) of 35S-labeled Trp100-Glu213 peptide
with various molar ratios (up to 50 ml) of unlabeled Pex14p, created by
in vitro transcription/translation, in 1 ml of TBST BLOTTO. In all
cases, membrane-bound radioactivity was determined by scintillation
counting. For all competitive binding assays, the amount of unlabeled
translation product was approximated from molar calculations of du-
plicate in vitro transcription/translation reactions in which products
were labeled with [35S]methionine, as above.
The specificity of binding of a PTS1-containing peptide to Pex5p was
tested by conjugating the peptide CRYHLKPLQSKL (which contains
the SKL PTS1 signal) or CRYHLKPLQLKS (a control peptide lacking
the signal) to SulfoLink Coupling Gel (Pierce, Rockford, IL), according
to the manufacturer’s protocol. 25 ml of gel conjugate was then mixed
with 35 ml of TBST buffer and 15 ml of either 35S-labeled Pex5p or
35S-labeled Pex14p, or 15 mg of purified GST-SH3 fusion protein, and
incubated for 16 h at 4 °C. Following incubation, the mixtures were
pelleted by centrifugation to yield a supernatant and gel pellet. The gel
pellet was washed four times with 1 ml of TBST and resuspended in a
final volume of 50 ml of TBST. Proportional volumes of supernatant and
pellet were resolved by SDS-polyacrylamide gel electrophoresis. 35S-
labeled proteins were visualized by autoradiography, and GST-SH3 was
detected by Western analysis using a rabbit anti-SH3 antibody (10).
The effect of PTS1 peptide loading of Pex5p was determined using
these same peptides. 50 ml of 35S-labeled Pex5p, created using coupled
in vitro transcription/translation, was incubated at 4 °C for 1 h with a
60 mM concentration of either peptide (19) in 1 ml of TBS BLOTTO.
These mixtures were then used to probe various membrane-immobi-
lized GST fusion constructs, as described above.
Three-dimensional Structural Modeling and Eisenberg Analysis—
The technique of protein modeling by homology (20) was used to assign
three-dimensional structure to the unknown structure of the Pex13p
SH3 domain based on structural information from Fyn, another mem-
ber of the SH3 domain family. The underlying principle of protein
modeling by homology is that within members of a protein family there
are structurally conserved regions that tend to be at the inner core of
proteins where differences in peptide chain topology would have signif-
icant effects on the overall conformation of the protein (20). Several
modeled proteins have been subsequently defined by x-ray crystallog-
raphy, demonstrating the success of this method (21, 22). Coordinates
were assigned from the crystal structure of the SH3 domain of Fyn
(pdblFyn.ent) (23) to the secondary structural regions of Pex13 protein
according to the alignment shown in Fig. 6A. All suitable loop struc-
tures were obtained by searching the Brookhaven Protein Data bank for
proteins containing loops of the same length joining similar secondary
structural units. All splice junctions were relaxed to a bond length of
1.34–1.37 Å and a bond angle greater than 166o. The resultant crude
model was then refined by energy minimization using Biosym’s consist-
ent valence force field to a convergence criterion of less than 1.0 kcal/
mol Å (maximum derivative). The accuracy of three-dimensional model
was tested using the Eisenberg method (24–26), which utilizes a com-
parison of the amino acid sequence of the protein with the model, using
a three-dimensional profile which is computed from the atomic coordi-
nates of the structure. Each residue in the three-dimensional model is
characterized by its environment, which is defined by the area of the
residue side chain that is buried in the protein structure, the fraction of
the side chain that is covered by polar residues, and the local secondary
structure. Thus the probability of finding each amino acid in the as-
signed environment is calculated from a three-dimensional–one-dimen-
sional scoring table derived from a statistical analysis of known protein
structures (26). The amino acid sequence of the protein is then com-
pared with the three-dimensional profile generated from the environ-
ment classifications and gives rise to an overall profile score and a
graphical presentation of the assessment (see inset graphs for Fyn and
Pex13 in Fig. 6B). The maximum expected score for a protein is given
by: Scalc 5 exp (20.833 1 1.008 3 length), where length is the number
of residues. Based on studies of all coordinate entries in the Brookhaven
Data Bank derived by x-ray, NMR, and computational methods, along
with a number of deliberately misfolded proteins, Eisenberg et al. (24)
suggest that a cutoff of , 0.45 3 Scalc is useful for identifying grossly
misfolded structures. Models with profile scores between 0.45 3 Scalc
and Scalc are considered correct, although it is still possible that locally
misfolded regions occur. It is suggested the examination of profile score
in a moving window scan of 10 residues is sufficient to identify locally
misfolded regions.
RESULTS
Pex5p Interacts with Pex13p and Pex14p in Vitro—The re-
sults of previous yeast studies have demonstrated that Pex5p
interacts with both Pex13p (10–12) and Pex14p (14). The for-
mer interaction has been proposed to occur via the SH3 domain
of Pex13p. To study these interactions in detail for the P.
pastoris proteins, we developed in vitro overlay binding assays
in which 35S-labeled “probe” proteins, generated by in vitro
transcription/translation (Fig. 1A), were tested for binding to
FIG. 1. In vitro synthesized radiolabeled proteins and recom-
binant GST fusion proteins used for in vitro binding assays. A,
autoradiographs of 35S-labeled Pex5p constructs and 35S-labeled
Pex14p synthesized by coupled transcription/translation in a reticulo-
cyte lysate and resolved by SDS-polyacrylamide gel electrophoresis.
pJEK4-3 indicates full-length Pex5p; pAU401, full-length Pex14p. The
other proteins in this figure are truncated Pex5p proteins. Note that the
plasmid pJEK5-4DNP8 produces two bands; the 41-kDa species is the
expected protein, the lower molecular mass species results from an
internal translation start site. Detailed information on the construction
of these proteins is presented under “Experimental Procedures”; a dia-
grammatic representation of each of these is shown in Fig. 8A. B,
Coomassie Brilliant Blue R stain of recombinant GST fusion proteins
resolved by SDS-polyacrylamide gel electrophoresis. In all cases, 3–5 mg
of recombinant protein was analyzed. GST is the GST control; GST-SH3
is GST fused to the Pex13p SH3 domain; GST-SH3-COOH is GST fused
to the region of Pex13p incorporating the SH3 domain through to the
carboxyl terminus; GST-MSH3-COOH is GST fused to the region of
Pex13p from the putative membrane domain through the SH3 domain
to the carboxyl terminus. The other proteins represent SH3 mutations;
the indicated amino acid substitutions are in the SH3 domain of the
parent GST-SH3 fusion protein. The migration of molecular mass
markers (in kDa) is indicated.
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purified GST fusion proteins (Fig. 1B) immobilized on nitrocel-
lulose membrane. The validity of these binding assays was
evaluated by immobilizing various amounts of purified GST-
SH3 fusion protein and probing with a constant amount of
Pex5p; complex formation, quantified as the amount of mem-
brane-bound radioactivity, increased with immobilized protein
in the range 0–16 mg (data not shown). In subsequent experi-
mentation we employed approximately 8 mg (0.2 nmol) of GST
fusion protein. Under these conditions, complex formation was
proportional to added 35S-labeled Pex5p translation product up
to the maximum volume tested of 50 ml (Fig. 2A) and was
competitively inhibited by the addition of unlabeled Pex5p
translation product (Fig. 2B). The inability to observe “stoichi-
ometric” competition in this latter experiment was because
saturation binding of GST-SH3 was not able to be achieved due
to the prohibitively large volumes of labeled Pex5p (i.e. trans-
lation product) required. This binding interaction was satura-
ble, however, as demonstrated in separate experiments using 2
mg of GST fusion protein (data not shown). We nevertheless
chose 8 mg of GST fusion protein for the routine binding assay
to ensure levels of bound radioactivity which would allow ac-
curate and reproducible comparisons among various protein
interactions.
The possible involvement of protein regions upstream and
downstream of the Pex13p SH3 domain in the interaction with
Pex5p was first clarified using different Pex13p fusion con-
structs. As shown in Fig. 3, which also serves to exemplify the
dot blot results obtained in these experiments, Pex5p bound all
of the GST-SH3 fusion proteins tested in these experiments,
but most effectively to that containing just the SH3 domain.
These data confirm that the SH3 domain alone is responsible
for binding to Pex5p. We also assessed Pex5p binding specific-
ity by testing for potential binding to another, related SH3
domain, that of the human Pex13 protein (10). These assays
showed that binding of 35S-labeled Pex5p to the GST-human
SH3 fusion protein was undetectable, being at the same level
as that for the GST control (data not shown).
An important initial question for these studies was whether
the preloading of Pex5p with a PTS1-containing protein, an
expected prerequisite for the docking of this cytoplasmic recep-
tor at the peroxisomal membrane, would influence the interac-
tion of this receptor with either Pex13p or Pex14p. We there-
fore synthesized two peptides, one containing a consensus
carboxyl-terminal PTS1 targeting signal, CRYHLKPLQSKL,
and a control peptide lacking this signal, CRYHLKPLQLKS.
The specificity of binding of the PTS1-containing peptide to
Pex5p was established by determining the binding of 35S-la-
beled Pex5p to agarose gel conjugated to either the PTS1 pep-
tide or the control peptide. These results are presented in Fig.
4A and show that Pex5p bound the PTS1 peptide but not the
FIG. 2. 35S-Labeled Pex5p binding
to the Pex13p SH3 domain in vitro
occurs in a dose-dependent manner
and is inhibited by the addition of
unlabeled Pex5p. A, increasing volumes
of in vitro synthesized 35S-labeled Pex5p
were added to 8 mg of GST-SH3 fusion
protein immobilized on nitrocellulose,
and the amount of bound radioactivity
was determined by scintillation counting.
B, increasing volumes of unlabeled in
vitro synthesized Pex5p were added with
a constant volume (25 ml) of 35S-labeled
Pex5p to 8 mg of nitrocellulose-immobi-
lized GST-SH3 fusion protein, and the
bound radioactivity was determined.
Bound radioactivity in the absence of un-
labeled Pex5p was set at 100% and repre-
sents the mean 6 S.E. of three experi-
ments. The Pex5p/35S-labeled Pex5p
molar ratio was determined as described
under “Experimental Procedures.”
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control peptide. In further experiments, we tested for possible
interaction of these same gel-conjugated peptides with Pex14p
and the Pex13p SH3 domain. In both cases, no binding was
observed (Fig. 4A).
Pex5p overlay binding assays were carried out with equimo-
lar amounts of immobilized GST-SH3 and GST-Pex14p in the
presence of these peptides separately. As shown in Fig. 4B,
Pex5p preloaded with the PTS1 peptide bound to both the
GST-Pex13p-SH3 fusion protein and to GST-Pex14p and min-
imally to the GST control fusion protein. Importantly, the
amount of Pex5p bound to Pex14p was 20–40 times greater on
a molar basis than that to Pex13p-SH3. Binding of Pex5p to
Pex13p almost doubled in the absence of the PTS1 peptide,
whereas Pex5p binding to Pex14p was reduced in the absence
of PTS1 peptide. The results presented here represent results
of assays carried out in the absence of 0.1% Tween 20 (see
“Experimental Procedures”). This modification to the binding
assay was introduced to test whether Pex5p binds PTS1 pep-
tides less efficiently in the presence of detergent; however, we
obtained essentially equivalent results whether detergent was
present or not (data not shown). Overall, these data suggest
that Pex5p binds more effectively to Pex14p when associated
with PTS1-containing cargo and to the Pex13p SH3 domain
when dissociated from cargo.
Pex14p has also been shown to interact weakly with the
Pex13p SH3 domain in Saccharomyces cerevisiae (13, 14, 27).
We were able to demonstrate this interaction for the P. pastoris
proteins using the in vitro binding assay (Fig. 5). This interac-
tion was less on a molar basis than that seen between Pex5p
and the Pex13p SH3 domain, but again it was more pronounced
with the GST-SH3 fusion protein that lacked SH3 domain
flanking regions.
Modeling of the Pex13p SH3 Domain—To provide a structure
suitable for undertaking mutagenesis of the Pex13p SH3 do-
main to address the observed interactions with both Pex5p and
Pex14p, the SH3 domain was modeled to the SH3 domain of
Fyn according to the principles of protein modeling by homol-
ogy. Recently, similar models have been used successfully to
design point mutation experiments to determine structure and
function of proteins and interactive residues (28). The crystal
structure of Fyn (pdblFyn.ent) (23) was selected as a suitable
template to model the Pex13p SH3 domain because compared
with other solved structures it has high resolution at 2.3 Å and
contains a synthetic ligand in its interactive region. In addi-
tion, there is significant sequence similarity (64%) between the
two SH3 domains with 35% identity over the co-linear align-
ment used for the modeling (Fig. 6A). The proposed model is
presented as a ribbon diagram in Fig. 6B. This model was
assessed by Eisenberg analysis, which gives an overall profile
score and a graphical presentation of the assessment (see inset
graphs for Fyn and Pex13p in Fig. 4B). The profile score of 21.0
(cutoffs 12.5–27.8) obtained for Pex13p indicates that this SH3
domain can achieve a fold similar to that of the Fyn SH3
domain, specifically the antiparallel five stranded b-sandwich.
One distinguishing feature of the Pex13p SH3 domain is the
extended n-Src loop between the second and third b-strands.
Mutations in the SH3 Domain Affect Pex13p Function in Vivo
and in Vitro—Studies on other SH3 domain-ligand interactions
have identified SH3 domain residues believed to be involved in
direct ligand binding or stabilization of the bound ligand com-
plex. These studies, when applied to the model proposed in Fig.
6, implied that the Pex13p SH3 domain residues Glu291,
Glu298, Glu318, Trp321, and Trp322 were potential candidate
residues involved in the interaction of the Pex13p SH3 domain
with Pex5p and Pex14p. We therefore modified these residues
by site-directed mutagenesis and tested the functional activity
of the mutated proteins both in vivo and in vitro. The in vivo
effect of these mutations was assessed as the ability of the
corresponding mutant Pex13 proteins to rescue the growth
deficiency of a pex13D strain on methanol-containing media, a
substrate that requires peroxisomal alcohol oxidase activity
and hence functional peroxisomes (29). As shown in Fig. 7A,
only expressed Pex13 proteins incorporating the E291K and
E296K mutations were unable to rescue growth of the pex13D
strain, implying loss of Pex13p function in vivo. The specific
biological consequences of these mutations were tested in the
in vitro assay, as the binding of radioactive Pex5p or Pex14p
(Fig. 7B). For Pex5p binding, the E291K and E296K mutations
again produced the most perturbation, reducing SH3 binding to
40% and 20%, respectively, of the wild-type level. E291Q and
E296Q, which neutralize the negative glutamic acid charge in
each case, reduced Pex5p binding only slightly. Mutation of a
glutamic acid residue in the n-Src loop, E318K, and the double
mutation targeting the conserved tryptophan residues, W321L/
FIG. 3. Pex5p binds to Pex13p through the SH3 domain. A, diagrammatic representation of the GST fusion proteins used: GST indicates
the GST control; GST-SH3, GST fused to the Pex13p SH3 domain; GST-SH3-COOH, GST fused to the region of Pex13p incorporating the SH3
domain through to the carboxyl terminus; GST-MSH3-COOH, GST fused to the region of Pex13p from the putative membrane domain through the
SH3 domain to the carboxyl terminus. B, the GST fusion proteins were immobilized on nitrocellulose membrane, probed with 35S-labeled Pex5p,
and then exposed to x-ray film. C, once probed, dots were excised from the nitrocellulose membrane, and bound radioactivity was measured by
scintillation counting. The level of bound 35S-labeled Pex5p is expressed as a percentage of that determined for the Pex5p/GST-SH3 interaction.
Values shown represent the mean 6 S.E. of triplicate values from one of three equivalent experiments.
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W322L, also resulted in some loss of Pex5p binding. For the
binding of Pex14p to the SH3 domain, the Glu291 and Glu296
mutations produced no deleterious effect, and the W321L/
W322L mutation reduced binding only slightly. The most dra-
matic result was obtained with the E318K mutation, which
effectively abolished Pex14p binding. These findings suggest
that Pex5p and Pex14p bind different sites on the Pex13p SH3
domain.
The Pex13p mutations were also evaluated for possible per-
turbation of the SH3 domain fold as a cause of disrupted
protein function. On the basis of energy calculations and profile
scores, none of the introduced mutations changed the predicted
SH3 fold to any significant degree; all of the Eisenberg scores,
a measure of the validity and accuracy of the predicted three-
dimensional models (24, 25), were within the acceptable range
expected for the wild-type SH3 fold (data not shown). Although
it should be noted that this computational analysis would not
detect changes that could affect post-translational folding, an-
other independent measure of correct structure and/or suscep-
tibility to proteolysis is the level of soluble fusion protein ex-
pression in E. coli (30). In this regard, none of the GST-SH3
fusion proteins was noticeably affected by the introduced mu-
tations (data not shown). These data imply that the observed
changes in binding activity are not caused by structural
changes in the SH3 domain per se but rather by perturbations
of the interactions between the SH3 domain and its ligand(s).
SH3 domain mutations thus affect the biological activity of
Pex13p, determined as the function of Pex13p in peroxisome
biogenesis in vivo and the binding of Pex5p and Pex14p in vitro.
Some of the observed changes in Pex13p function in vivo are
consistent with disruption of the binding of the Pex13p SH3
domain to Pex5p, for example, effects of the E291K and E296K
mutations. Other data, however, indicate a lack of correlation
between effects noted in vitro and those in vivo. One explana-
tion for these differences is that particular SH3 domain mu-
tants may still retain residual Pex13p activity in vivo. Another
possible explanation is that the effects of the SH3 modifications
may be complicated by the interaction of this domain with
binding partners, including Pex5p and Pex14p.
Mapping of the Pex13p Binding Site in Pex5p—The Pex5p
blot overlay was utilized further to determine the SH3 binding
region in Pex5p. In these experiments, Pex5p constructs gen-
erated by deletion mutagenesis and labeled using in vitro tran-
scription/translation were used to probe nitrocellulose-immobi-
lized GST-SH3 fusion proteins. To allow a more quantitative
assessment of relative binding efficiencies, Pex5p constructs
were added at equivalent molar ratios determined by the level
of radioactive incorporation in each case. The results are shown
in Fig. 8. The carboxyl-terminal half of Pex5p, which contains
the PTS1-binding TPR domain (4), did not bind the Pex13p
SH3 domain. The binding site was found to reside instead in
the amino-terminal half of the protein. The minimal Pex5p
sequence that produced quantitative binding under these con-
ditions was that encoded by pAU211 and corresponding to
residues Trp100-Glu213, a peptide of approximately 12.7 kDa.
Deletion of sequence both amino-terminal and carboxyl-termi-
nal to this peptide resulted in minimal loss of binding activity;
the extreme amino-terminal region of Pex5p per se had no
binding activity (Fig. 8A). The Trp100-Glu213 peptide sequence
contains no proline-rich peptide. It does, however, include a
number of pentapeptide loose repeats of the form WXQXF/
WXDQF (downward pointing arrows in Fig. 8A) (4, 18) and a
high content of glutamine residues (19.5%). In separate exper-
iments, we have been unable to demonstrate that a synthetic
FIG. 4. PTS1 peptide loading of Pex5p modifies its interaction
with Pex14p and the Pex13p SH3 domain. A, the specificity of
binding of Pex5p to a PTS1 peptide was tested by in vitro binding
assays. Cross-linked agarose gel coupled to either a PTS1-containing
peptide CRYHLKPLQSKL (1SKL) or a control peptide CRYHLK-
PLQLKS (1LKS), was incubated with in vitro synthesized 35S-labeled
Pex5p, 35S-labeled Pex14p, or purified recombinant GST-SH3 fusion
protein. After incubation, the bound and unbound material was sepa-
rated into pellet and supernatant fractions by centrifugation. Equal
proportions of pellet (P) and supernatant (S) fraction were resolved by
SDS-polyacrylamide gel electrophoresis and analyzed by autoradiogra-
phy (Pex5p and Pex14p) or Western blotting using an anti-SH3 anti-
body (GST-SH3). B, the effect of added PTS1-containing peptide on the
in vitro binding of Pex5p to GST (left panel), GST-Pex14p (middle
panel), and GST-SH3 (right panel) was determined using the dot blot
assay. Dark bars (1SKL), PTS1-containing peptide CRYHLKPLQSKL;
light bars (1LKS), control peptide CRYHLKPLQLKS. Binding is ex-
pressed as the mean 6 S.E. of triplicate values from one of three
equivalent experiments; *p , 0.05, **p , 0.01 compared with the 1SKL
assay result.
FIG. 5. Pex14p binds to the SH3 domain of Pex13p. The binding
of Pex14p to GST-SH3 fusion proteins (dark bars) was determined as
described under “Experimental Procedures.” Data are expressed as a
percentage of the molar in vitro binding of Pex5p to GST-SH3 (light bar)
measured under equivalent conditions. Values shown are the mean 6
S.E. of triplicate values from one of two equivalent experiments.
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peptide, QTQWEDQFKDI, which contains the sequence of one
of these motifs, displaces Trp100-Glu213 peptide binding to the
Pex13p SH3 (data not shown). We tested for the specificity of
binding of the Trp100-Glu213 peptide to GST-SH3 by substitut-
ing the GST-SH3 point mutants used previously. As with full-
length Pex5p, the E291K and E296K substitutions reduced
peptide binding. More significant reduction of binding of this
peptide, compared with that using the full-length Pex5p, was
observed with the E291Q, W321L/W322L, and E318K SH3
mutants (Fig. 8B). The Trp100-Glu213 peptide also competed
with full-length Pex5p for binding to the GST-SH3 fusion pro-
tein in a dose-dependent manner (Fig. 8C). These data are
consistent with the SH3 binding site of Pex5p being located
within the sequence encompassed by the Trp100-Glu213 peptide.
We also attempted to identify the Pex14p binding site in
Pex5p. These experiments indicated that the carboxyl-terminal
region of Pex5p did not bind Pex14p, whereas the entire amino-
terminal half of the protein did bind (data not shown). Signif-
icantly, the Trp100-Glu213 peptide did not bind Pex14p, results
that suggest that different sites in Pex5p interact with Pex14p
and the Pex13p SH3 domain. Further research will be required
to determine the nature of the Pex14p binding site.
Pex5p and Pex14p Compete for Binding to the Pex13p SH3
Domain—As noted above, both Pex5p and Pex14p are able to
bind the Pex13p SH3 domain, albeit with different apparent
affinities. The identification of the Pex5p Trp100-Glu213 peptide
provided a means of testing possible binding competition of
Pex5p and Pex14p for the Pex13p SH3 domain; the Trp100-
Glu213 peptide does not bind to Pex14p, thereby obviating the
complication of ternary interaction among the full-length
Pex5p, Pex14p, and Pex13p SH3 domain. As shown in Fig. 9,
Pex14p competed with Pex5p for binding to the SH3 domain.
Together with the results on the effects of the different SH3
mutations, these results suggest that the Pex5p and Pex14p
binding sites in the SH3 domain overlap. The region of Pex14p
which interacts with the SH3 domain has not been identified.
Interestingly the P. pastoris Pex14p contains a putative class II
SH3 ligand, APPLPER,2 and it has been shown recently that
mutation of the identical ScPex14p peptide abolished its bind-
ing to the ScPex13p SH3 domain, suggesting that this is the
SH3 domain ligand (13). We would note that using our dot blot
experiments, we have been unable to demonstrate displace-
ment by this peptide of the binding of Pex14p to the SH3
domain (data not shown), but we concede that possible reasons
for this may include the low affinity of this interaction and the
need for flanking residues present in the full-length Pex14p to
achieve a higher affinity interaction.
DISCUSSION
The data presented in this report shed new light on the
possible roles of Pex14p and Pex13p in importing PTS1 pro-
teins into the peroxisomal lumen. First, both of these proteins
have been shown to interact with Pex5p, the PTS1 receptor,
with the interaction with Pex14p predominating when based
FIG. 6. A three-dimensional model
of the Pex13p SH3 domain. A, se-
quence alignment of the SH3 domain of
Fyn and the putative SH3 domain of
Pex13p, for which numbering is shown.
Boxed regions show the alignment of con-
served secondary structures, b-1 to b-5
indicate b-sheets, and a indicates an
a-helix that has been derived from the
crystal structure of Fyn (pbd1Fyn.ent).
b-Turns were assigned according to the
promotif program within the InsightII
package. B, solid ribbon representations
of the crystal structure of Fyn SH3 do-
main (left, blue) with the peptide PPAYP-
PPPVP (purple) in the ligand binding
groove. The modeled SH3 domain of
Pex13p (right, green) has five amino acids
(Glu291, Glu296, Glu318, Trp321, and
Trp322) solid rendered in red to show their
respective positions to the putative ligand
binding groove. Glu291 and Glu318 also
serve to indicate the positions of the RT
and n-Src loops, respectively. To assist
with orientation and comparison of do-
mains, the conserved tryptophans of Fyn
(Trp321 and Trp322 of Pex13p) have also
been solid rendered and are shown in
their positions as determined by crystal-
lography. The Eisenberg analysis and
profile score of both the crystal structure
of Fyn and the modeled Pex13p SH3 do-
main are shown below their respective
structures. The numbers below the
graphs indicate the amino acids of their
respective proteins. The Fyn crystal an-
notation includes amino acids represent-
ing its proline-rich ligand. The y axis rep-
resents the Scalc score for a window of 10
amino acids. The red horizontal line on
these graphs represents the minimal cut-
off (0.0); no regions of the modeled Pex13p
SH3 domain fall below this limit (for more
details, see “Experimental Procedures”).
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on the molar ratio of bound Pex5p. Second, we have established
that the loading of Pex5p with PTS1 peptide has provided a
means of differentiating the different functions of Pex13p and
Pex14p in the PTS1 import pathway. Specifically, loading of
Pex5p with PTS1 peptide enhances its interaction with Pex14p
but diminishes that with Pex13p. Taken together, these obser-
vations suggest a sequence of interaction of Pex5p with these
two membrane components in which cargo-laden Pex5p is first
docked at the peroxisome membrane via interaction with
Pex14p. Subsequent to, or coincident with, release of this PTS1
protein cargo, Pex5p is shifted to Pex13p (Fig. 10). The reason
for the shift of Pex5p from Pex14p to Pex13p is not yet clear but
may provide a means by which the receptor is able to cycle back
to the cytoplasm. The possible influence of other proteins in
this proposed receptor transfer mechanism has not been ad-
dressed in this study.
The existence of this receptor docking complex raises some
interesting questions about the nature of the individual com-
ponent interactions. The data presented here confirm the con-
tention by us and others that the SH3 domain of Pex13p is
indeed the region of Pex13p required for the interaction with
Pex5p. Implicit in this hypothesis is that the region of Pex5p
involved in this SH3 interaction is separate from the region
required for recognition of nascent PTS1 proteins. It is now
well established that the TPR domain of Pex5p, located in the
carboxyl-terminal half of the protein, is responsible for PTS1
FIG. 7. The effect of SH3 domain mutations on Pex13p function
in vivo and binding to Pex5p and Pex14p in vitro. A, activity of
Pex13p proteins containing SH3 mutations when assessed as the
growth of yeast (A600) in methanol-containing media, as described un-
der “Experimental Procedures.” l, wild-type SH3; f, E291K; M,
E291Q; l , E296K; E, E296Q; , E318K; and , WW321/322LL. B, in
vitro binding of 35S-labeled Pex5p (left panel) and 35S-labeled Pex14p
(right panel) to GST-SH3 fusion proteins tested using the dot blot
method described under “Experimental Procedures.” Binding is ex-
pressed as a percentage of that determined for the wild-type (wt) GST-
SH3 fusion protein. Values represent the mean 6 S.E. of triplicate
values from one of two to four equivalent experiments.
FIG. 8. Determination of the Pex13p SH3 domain binding site
in Pex5p. A, Pex5p was modified by deletion mutagenesis, labeled with
[35S]methionine by in vitro transcription/translation, and tested for
binding to the GST-SH3 fusion protein in the dot blot assay. Left panel,
mutant protein designation with Pex5p amino acid numbering shown.
pJEK4-3(1–576) corresponds to the wild-type protein; middle, diagram-
matic representation of Pex5p mutant proteins, prepared as described
under “Experimental Procedures.” The closed circle indicates amino-
terminal residues 1–12; arrows show the positions of the WXQXF/
WXDQF repeats; the hashed box is the TPR domain region. Right panel,
relative binding of the Pex5p mutant proteins to immobilized GST-SH3
fusion protein, based on the results of two to five independent experi-
ments. 11111 represents greatest binding, 2 represents low to un-
detectable binding. B, in vitro binding of the 35S-labeled Pex5p peptide
Trp100-Glu213 (construct pAU211) to GST-SH3 fusion proteins. Binding
is expressed as the percentage of that determined with wild-type SH3
(GST-SH3) and is expressed as the mean 6 S.E. of triplicate assays
from one of two to three equivalent experiments. C, competitive binding
assay between various amounts of unlabeled Trp100-Glu213 peptide and
a constant amount of 35S-labeled Pex5p for membrane-immobilized
GST-SH3 fusion protein. The Trp100-Glu213 peptide/Pex5p molar ratios
were determined as described under “Experimental Procedures.” Bind-
ing is expressed as the mean 6 S.E. of triplicate values from one of three
equivalent experiments.
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signal recognition and binding (4, 5). Not surprisingly then, our
data here show that the SH3 binding region of Pex5p is distinct
from the TPR domain and is situated instead in the amino-
terminal half of the protein. Our preliminary data on the
Pex14p binding site in Pex5p are consistent with this site also
lying in the amino-terminal half of the protein, albeit separate
from the SH3 binding site, a result that accords with recent
findings on the interaction of human Pex14p with Pex5p (31).
These distinct structural features of Pex5p are consistent with
a tri-functional role of this receptor in terms of protein inter-
action:, PTS1 protein recognition in the cytoplasm, peroxisomal
membrane docking of this receptor-protein complex at Pex14p,
and displacement of the unloaded Pex5p to Pex13p.
Our results indicate that Pex14p and Pex5p compete for
binding to the SH3 domain of Pex13p. A number of questions
arise as to the mechanisms by which this SH3 domain manages
two different binding partners. SH3 ligands are assumed to
comprise peptides that form left-handed helices and are there-
fore normally, though not always, proline-rich peptides (32,
33). Promiscuous behavior of SH3 domains in ligand binding is
not new. Recently, for example, the Btk SH3 domain has been
shown to bind two partners, although in this case both ligands
were of the classical polyproline structure (34). The P. pastoris
Pex14p contains a putative class II ligand, APPLPER,2 and the
identical peptide is found in the S. cerevisiae Pex14p (14). Both
of these proteins interact weakly with their cognate Pex13p
SH3 domains (this study; 14). A recent report on the S. cerevi-
siae proteins has shown that mutations in this polyproline
ligand disrupt the interaction of Pex14p with the Pex13p SH3
domain (13). The SH3 binding region of Pex5p, on the other
hand, appears to represent a different type of SH3 ligand in
that Pex5p does not contain proline-rich stretches and there-
fore does not apparently fit with the classical structure of such
ligands. Whether elements of this peptide sequence do form a
non-proline left-handed helix is unknown. One identifiable fea-
ture of the SH3 binding site of Pex5p is the presence of pen-
tapeptide repeat motifs WXQXF/WXDQF, a feature also appar-
ent in the S. cerevisiae and human Pex5 proteins (18). Our
binding data here, however, indicate that a single motif alone is
not effective in competitive inhibition of the binding between
the Pex5p Trp100-Glu213 peptide and the SH3 domain; in addi-
tion, the Trp100-Glu213 peptide, which contains all of the Pex5p
pentapeptide repeats, was the minimal effective binding se-
quence in our studies. Thus the SH3 domain binding site in
Pex5p may be significantly different from classical ligands in
both sequence and length. The paper by Schliebs and co-work-
ers (31) is relevant here. The authors note that these pentapep-
tide repeats form amphipathic a-helices and speculate that
they may be binding sites, not for the SH3 domain but instead
for Pex14p. In view of this suggestion, it is unclear as to why
the Pex5p Trp100-Glu213 peptide, which contains all of the
pentapeptide repeats in P. pastoris Pex5p, did not bind Pex14p
in our experiments; but again, this may have to do with the
requirement in these interactions for flanking or other regions
of Pex5p.
The other interesting feature of the Pex13p SH3 domain is
the extended n-Src loop. Whether this loop confers unusual
ligand specificity is not known. A specific involvement of acidic
residues was tested in these studies in light of other studies
(35) that have implicated salt bridge formation between SH3
glutamic acid residues and arginine residues in the binding
ligand. Substitution of an n-Src loop glutamic acid residue
(E318K) was the only mutation tested which abolished binding
to both Pex14p and the Pex5p Trp100-Glu213 peptide, a result
that suggests that this loop is required for the interactions with
both Pex14p and Pex5p. In contrast, Pex5p, but not Pex14p,
binding was also attenuated by similar substitutions of two
RT-loop glutamic acid residues (Glu291 and Glu296), suggesting
that Pex5p binding involves this loop as well. The n-Src loop
and the RT loop define the spatial arrangement of the Pex13p
SH3 domain putative ligand binding groove. If Pex14p and
Pex5p do in fact behave like classical SH3 ligands and interact
by binding to the SH3 ligand binding groove, the possible
different positioning of these ligands in and around this groove
is germane to an understanding of the mechanisms involved.
Our data suggest that the Pex14p class II ligand may occupy a
relatively small space of the SH3 groove close to the n-Src loop.
In contrast, if, as our data suggest, the Pex5p ligand is larger
and more structurally complex, it may occupy a greater space
in the groove as well as exterior to the SH3 domain and thus
involve both the n-Src and RT loops. In this model, competition
for SH3 domain binding by Pex5p and Pex14p would be pri-
marily regulated by the n-Src loop, the length of which in
Pex13p is atypical in the SH3 protein family. It is of interest
here that only the E291K and E296K mutations suppressed
FIG. 9. Pex14p and the Pex5p Trp100-Glu213 peptide compete
for binding to the Pex13p SH3 domain. A constant amount of
35S-labeled Pex5p Trp100-Glu213 peptide and increasing amounts of
unlabeled Pex14p, both generated by in vitro transcription/translation,
were tested for binding to the GST-SH3 fusion protein using the dot blot
assay. The Pex14p/Trp100-Glu213 peptide molar ratios were determined
as described under “Experimental Procedures.” The amount of mem-
brane bound radioactivity is expressed as the mean 6 S.E. of triplicate
values from one of two equivalent experiments
FIG. 10. Model for the import of PTS1-containing proteins into
the peroxisome. The docking of the PTS1 protein-Pex5p complex at
the peroxisome membrane occurs at Pex14p and is mediated by the
amino terminus of Pex5p. A region containing the pentapeptide repeats
is indicated by arrows. The PTS1 protein is subsequently dissociated
and imported into the peroxisome. Concomitant with, or following, this
event, Pex5p shifts to the SH3 domain region of Pex13p from which it
may recycle to the cytoplasm. Although the fate of Pex7p in this model
is not clear, it could be speculated that a similar mechanism might
operate commencing with the docking of this protein at Pex14p followed
by its displacement to the amino-terminal region of Pex13p.
Interaction of Pex5p with Peroxisomal Pex14p and Pex13p 4135
 at UQ Library on October 25, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Pex13p function in vivo. The reason for this is not clear but may
reflect greater functional significance of the interaction of the
SH3 domain with Pex5p over that with Pex14p. For the S.
cerevisiae proteins, Pex13p SH3 binding to Pex14p is not es-
sential for membrane association of Pex14p (13). Binding of
Pex5p to the Pex13p SH3 domain, on the other hand, may
represent a biological imperative; in our model this would be
the Pex13p-mediated shuttling of Pex5p back to the cytoplasm.
The mechanism by which Pex5p may be shuttled from
Pex14p to Pex13p has not been directly addressed in these
studies, but the speculation by Schliebs et al. (31) that the
pentapeptide motifs of Pex5p, in representing potentially dif-
ferent affinity binding sites for Pex14p, is intriguing in that it
may provide a means of transferring Pex5p along Pex14p for
transfer to the Pex13p SH3 domain. The interaction observed
between Pex14p and the Pex13p SH3 domain may also contrib-
ute to the mechanisms proposed here. This apparent low affin-
ity interaction between these components may represent a
transient interaction to allow Pex5p transfer. It is also tempt-
ing to speculate here that the pentapeptide repeats of Pex5p
may function in a manner similar to that proposed above to
enable Pex5p detachment from the Pex13p SH3 domain for
cycling back to the cytoplasm.
The role of Pex7p, the PTS2 receptor, in this putative import
complex has not been addressed in these studies. Pex14p was
characterized initially as the membrane docking factor for
Pex7p (14), but recently it has also been shown that Pex13p
functionally interacts with Pex7p via a cytoplasmically ori-
ented amino-terminal region, with this complex enabling the
interaction between Pex5p and Pex7p (13). Further studies will
be required to incorporate Pex7p into this emerging model and
to provide links between PTS1 and PTS2 protein import.
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